BeautyHealth's first quarter net sales reached $81.4 million, a decrease of (5.7)% compared to the same period in 2023, with lower equipment sales offset by growth in consumables. The company reported a net loss of $(0.7) million, an improvement from the prior year, and an adjusted EBITDA of $0.4 million.
Net sales for the first quarter of 2024 were $81.4 million, a decrease of (5.7)% compared to the prior year period, due to lower delivery systems net sales.
Gross margin was 59.4% in Q1 2024, compared to 62.7% in Q1 2023, with adjusted gross margin at 63.4% versus 70.0% in the prior year.
Net loss was $(0.7) million in Q1 2024, compared to a net loss of $(20.3) million in Q1 2023, primarily due to the gain on repurchase of convertible notes.
Adjusted EBITDA was $0.4 million in Q1 2024, compared to adjusted EBITDA of $(0.5) million in Q1 2023, primarily due to lower operating expenses.
The company expects second quarter net sales between $96 and $102 million and adjusted EBITDA between $4 and $7 million. For fiscal year 2024, the company anticipates flat to low-single digit % growth in net sales and adjusted EBITDA greater than $40 million.
Visualization of income flow from segment revenue to net income